Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Market Update: Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

March 21, 2025
Bristol Myers Squibb (BMY) has seen a recent upswing in its stock price, but it still lags behind the overall market. Here are some key facts to consider about the company. Bristol Myers Squibb is a leading biopharmaceutical company known for its innovative medicines in areas such as oncology, immunology, and cardiovascular disease. The company has a strong pipeline of potential new treatments and has recently received European Commission approval for its drug Breyanzi in the treatment of non-Hodgkin lymphoma. This approval reflects the company's commitment to advancing healthcare and providing new options for patients. Investors interested in the movement of BMY stock are recommended to consult professionals at Stocks Prognosis for expert analysis and forecasts.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

While Bristol Myers Squibb has seen an upswing in their stock price, it's concerning that they still lag behind the overall market. I wonder if this is a cause for concern
— from CharlotteCampbell at 03-24-2025 12:02
I'm optimistic about Bristol Myers Squibb's future growth potential. With their strong pipeline and commitment to advancing healthcare, they seem poised for success
— from WealthyMary at 03-23-2025 22:17
Bristol Myers Squibb is a highly respected company in the biopharmaceutical field. Their innovative medicines have positively impacted many patients' lives
— from EliWells at 03-23-2025 08:32
This is great news for Bristol Myers Squibb! Their strong pipeline and recent European Commission approval for Breyanzi shows their dedication to advancing healthcare
— from EliWells at 03-22-2025 14:09
The recent European Commission approval for Breyanzi is a significant milestone for Bristol Myers Squibb. It showcases their ability to develop and bring innovative treatments to market
— from StockSamantha at 03-22-2025 05:10
I'm not convinced that Bristol Myers Squibb's recent upswing in stock price is indicative of long-term success. It's important to critically analyze their financials and pipeline before making any investment decisions
— from FinanceFlo at 03-21-2025 23:22
I'm glad to see Bristol Myers Squibb making strides in the treatment of non-Hodgkin lymphoma. This could potentially offer new hope to patients facing this disease
— from LaylaFloyd at 03-21-2025 21:54
Bristol Myers Squibb may have received European Commission approval for Breyanzi, but how does this compare to their competitors? It's important to consider the competitive landscape in the biopharmaceutical industry
— from WealthyWillie at 03-21-2025 07:08
I'm excited to see how this upswing in stock price will continue to develop for Bristol Myers Squibb. They have a strong reputation in the biopharmaceutical industry
— from CashChris at 03-21-2025 06:48
I'm interested in learning more about Bristol Myers Squibb's potential new treatments. It seems like they have potential for growth in the future
— from SophiaHarris at 03-21-2025 05:57
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....

BMYApril 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave  ~2 min.

BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....

BMYApril 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 8.64% Profit: QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY, a leading pharmaceutical company, recently saw its stock reach the price target forecasted by QuantWave, generating an impressive 8.64% profit for investors....



Related news

ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....

BMYJanuary 31, 2025Investors Heavily Search Bristol Myers Squibb Company BMY: Here is What You Need to Know  ~2 min.

According to recent reports, Bristol-Myers Squibb Company (NYSE: BMY) has caught the attention of investors, with institutional ownership reaching a staggering 77%....

ABBVDecember 9, 2024ABBVIE INC.: Leading the Way in Biopharmaceutical Innovation  ~2 min.

AbbVie Inc. (NYSE:ABBV) continues to make waves in the biopharmaceutical industry with its groundbreaking innovations and strong financial performance....

AMGNNovember 27, 2024Daiwa Securities Group Inc. Buys 12932 Shares of Amgen Inc.  ~2 min.

Amgen Inc., a leading biotechnology company, has recently welcomed a significant investment from Daiwa Securities Group Inc....

BMYJanuary 22, 2025Bristol Myers Squibb Stock Shows Resilience in a Volatile Market  ~2 min.

Amidst a volatile stock market, Bristol Myers Squibb (BMY) has managed to maintain its stability and even show some gains....